Dr Stephen Rosevear joins Cogent as director of Research & Policy
February 7, 2012Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Cogent, Stephen Rosevear
Prior to joining Cogent, Stephen was HMRC’s chief analyst on the corporate real estate market, undertaking tax modeling and policy development for …
Roche rounds off year with solid performance
February 3, 2012Sales and Marketing Roche
A strong performance in its diagnostics division was among the factors enabling Roche to deliver a solid set of results …
Andrew Morgan joins Republic M!
February 2, 2012Business Services, Medical Communications, Sales and Marketing Andrew Morgan, Republic M!
Republic M! has strengthened its team with the appointment of Andrew Morgan as head of operations. Andrew has leadership expertise …
Merck posts strong results for 2011
February 2, 2012Sales and Marketing Frazier, Merck, Singulair, Victrelis
Foreign exchange rates and strong sales from established products helped Merck to achieve single-digit growth for 2011. The US firm …
Working Life: Carlos Gallardo, general manager, Almirall
February 2, 2012Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Almirall, Carlos Gallardo
BiographyCarlos Gallardo is general manager of the Almirall UK and Ireland affiliate from its creation in 2008. He has an …
AstraZeneca to cut 7,300 jobs as growth stalls
February 2, 2012Business Services, Manufacturing and Production, Research and Development, Sales and Marketing AZ, AstraZeneca, David Brennan, R&D
AstraZeneca will make 7,300 cuts to its sales and R&D staff by 2014, but the company has not yet said …
Pfizer recalls oral contraceptive for packaging errors
February 2, 2012Manufacturing and Production Akrimax, Bedford, Cephalon, Lo/Ovral-28, Pfizer, Teva
Pfizer has been forced to recall a large volume of oral contraceptive packs distributed in the US market because a …
Zytiga cost too high, says NICE
February 2, 2012Sales and Marketing NICE, Zytiga
NICE is not recommending Janssen’s prostate cancer pill Zytiga because of its high cost. Zytiga (abiraterone) is not recommended, in …
RSA announces promotions
February 2, 2012Medical Communications, Sales and Marketing rsa
Life sciences executive search and interim management specialist firm RSA, has announced its latest promotions.John Callagher (pictured) has been promoted …
Sigma-Aldrich acquires testing company BioReliance
February 1, 2012Research and Development Sigma-Aldrich
Sigma-Aldrich has acquired clinical testing company BioReliance for $350 million. Purchased from Avista Capital Partners, BioReliance provides services that include …
Pfizer weathers patent expiry storm
February 1, 2012Pfizer has managed to keep its head above water in its full year results, but faces a tough 2012 without …
Latest content
Pharma sees climate disruption as growing supply-chain risk
Manchester NHS-MHRA partnership to test new technologies in real-world care
